Journal Mobile Options
Table of Contents
Vol. 56, No. 1, 2006
Issue release date: September 2006
Eur Neurol 2006;56:1–5
(DOI:10.1159/000094248)

Facioscapulohumeral Muscular Dystrophy and Occurrence of Heart Arrhythmia

Trevisan C.P. · Pastorello E. · Armani M. · Angelini C. · Nante G. · Tomelleri G. · Tonin P. · Mongini T. · Palmucci L. · Galluzzi G. · Tupler R.G. · Barchitta A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Subjects with facioscapulohumeral muscular dystrophy (FSHD) do not generally suffer from significant cardiac symptoms. Although with heterogeneous results, studies reported to date indicate that heart alterations unrelated to cardiomyopathy are possible in FSHD. Patients and Methods: We describe the findings of a multicenter investigation aimed at detecting cardiac abnormalities in 83 FSHD patients, 44 males and 39 females with a mean age of 47 years. All patients underwent clinical heart examination, 12-lead electrocardiography and 24-hour Holter monitoring; echocardiography was also performed on most patients. Results: Among the 83 patients, 62 with no cardiovascular risk factors were identified. Ten of them manifested clinical or subclinical cardiac involvement: 5 reported symptoms represented mostly by frequent palpitations secondary to supraventricular arrhythmia and another 5 exhibited electrocardiographic signs of short runs of supraventricular paroxysmal tachycardia. In the absence of cardiovascular risk factors, we found symptoms or signs of heart involvement of mainly arrhythmic origin in 10 of our 83 FSHD patients (12%). Conclusions: Considering our data and those available in the literature as a whole, arrhythmic alterations seem to be detected more frequently than expected in FSHD patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fitzsimons RB: Facioscapulohumeral muscular dystrophy (review). Curr Opin Neurol 1999;12:501–511.
  2. Tawil R, Griggs RC: Facioscapulohumeral dystrophy; in Karpati G, Hilton-Jones D, Griggs RC (eds): Disorders of Voluntary Muscle. Cambrige, Cambrige University Press, 2001, pp 464–470.
  3. Wijmenga C, Frants RR, Brouwer OF, Moerer P, Weber JL, Padberg GW: Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990;336:651–653.
  4. Van Deutekom JC, Wijmenga C, Van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, et al: FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;12:2037–2042.

    External Resources

  5. Lunt PW: 44th ENMC international workshop: facioscapulohumeral muscular dystrophy – molecular studies (19–21 July 1996, Naarden, The Netherlands). Neuromuscul Disord 1998;8:126–130.
  6. Gabellini D, Tupler R, Green MR: Transcriptional derepression as a cause of genetic diseases. Curr Opin Genet Dev 2003;13:239–245.
  7. Tupler R, Gabellini D: Molecular basis of facioscapulohumeral muscular dystrophy. Cell Mol Life Sci 2004;61:557–566.
  8. Bushby K, Muntoni F, Bourke JP: 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy (7–9 June 2002, Naarden, The Netherlands). Neuromuscul Disord 2003;13:166–172.
  9. Gardner-Medwin D, Walton J: The muscular dystrophies; in Walton J, Karpati G, Hilton-Jones D (eds): Disorders of Voluntary Muscle. Edinburgh, Churchill Livingstone, 1994, pp 543–594.
  10. Padberg GW, Lunt PW, Koch M, Fardeau M: Facioscapulohumeral muscular dystrophy; in Emery AEH (ed): Diagnostic Criteria for Neuromuscular Disorders. Baarn, ENMC, 1997, pp 9–15.
  11. Faustmann PM, Farahati J, Rupilius B, Dux R, Koch MC, Reiners C: Cardiac involvement in facio-scapulo-humeral muscular dystrophy: a family study using thallium-201 single-photon-emission-computed tomography. J Neurol Sci 1996;144:59–63.
  12. Finsterer J, Stollberger C, Meng G: Cardiac involvement in facioscapulohumeral muscular dystrophy. Cardiology 2005;103:81–83.
  13. Galetta F, Franzoni F, Sposito R, Plantinga Y, Femia FR, Galluzzi F, et al: Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2005;15:403–408.
  14. Kimura T, Moriwaki T, Savada J, Naka T, Hazama T, Nakata T: A family with facioscapulohumeral muscular dystrophy and hereditary long QT syndrome (in Japanese). Rinsho Shinkeigaku 1997;37:690–692.
  15. Laforet P, de Toma C, Eymard B, Becane HM, Jeanpierre M, Fardeau M, et al: Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 1998;51:1454–1456.
  16. Stevenson WG, Perloff JK, Weiss JN, Anderson TL: Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292–299.
  17. Baldwin BJ, Talley RC, Johnson C, Nutter DO: Permanent paralysis of the atrium in a patient with facioscapulohumeral muscular dystrophy. Am J Cardiol 1973;31:649–653.
  18. Caponnetto S, Pastorini C, Tirelli G: Persistent atrial standstill in a patient affected with facioscapulohumeral dystrophy. Cardiology 1968;6:341–350.

    External Resources

  19. De Visser M, de Voogt WG, la Riviere GV: The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15:591–596.
  20. Galluzzi G, Deidda G, Cacurri S, Colantoni L, Piazzo N, Vigneti E, et al: Molecular analysis of 4q35 rearrangements in fascioscapulohumeral muscular dystrophy (FSHD): application to family studies for a correct genetic advice and a reliable prenatal diagnosis of the disease. Neuromuscul Disord 1999;9:190–198.
  21. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al: Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol 1998;31:150–157.
  22. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, et al: Mapping of a gene for long QT syndrome to chromosome 4q25–27. Am J Hum Genet 1995;57:1114–1122.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50